GMDA News and Press, Gamida Cell Ltd. From 10/09/23

2023-10-09 08:23:30 ET More on InMode, Mirati Therapeutics, etc. InMode: Bullish Support Failed To Materialize InMode: Strong Net Cash Position Sets The Stage For Opportunistic Buybacks InMode: Be Greedy When Others Are Fearful Bristol-Myers Squibb to acquire...

Abbey Jenkins, President and Chief Executive Officer, to also participate in the panel “A record setting year for cell and gene therapies – how do we keep the momentum going?” Gamida Cell Ltd . (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into po...

Gamida Cell Ltd . (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that it will be presenting at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023) taking place in San Diego, CA and virtually November 1-5, 202...

Omisirge is the only allogeneic stem cell therapy approved by the U.S. Food and Drug Administration (FDA) on the basis of a global randomized Phase 3 trial Rapid onboarding of transplant centers and significant payer coverage demonstrate strong launch progress Gamida Cell Ltd ...

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that its management team will present corporate highlights at the upcoming H.C. Wainwright 25 th Annual Global Investment Conference in New York, NY. Presentat...

2023-08-14 19:02:02 ET Summary Gamida Cell's approved therapy, Omisirge, shows faster neutrophil recovery and reduced infections in blood cancer patients compared to standard care. The long-term study of Omisirge includes a diverse patient population, improving its marketability. ...

2023-08-14 13:12:05 ET Gamida Cell Ltd. (GMDA) Q2 2023 Earnings Conference Call August 14, 2023, 08:30 AM ET Company Participants Mike Kuczkowski - Corporate Communications Abbey Jenkins - President and CEO Michele Korfin - COO and Chief Commercial Officer Ro...

2023-08-14 07:29:28 ET Gamida Cell press release ( NASDAQ: GMDA ): Q2 GAAP EPS of -$0.31 misses by $0.11 . As of June 30, 2023, Gamida Cell had total cash and cash equivalents of $54.1 million compared to $64.7 million as of December 31, 2022. The company expects i...

Strong start for Omisirge ® (omidubicel-onlv) launch with significant payer coverage and number of transplant centers onboarded exceeding expectations Company continues to pursue strategic partnership to further support Omisirge launch Cash runway extended into Q2 2024; b...

Conference Call and Webcast Scheduled for Monday, August 14 th at 8:30 am Eastern Time Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the second qua...